Adherence to treatment with selective serotonin reuptake inhibitors and the risk for fractures and bone loss: A population-based cohort study

CNS Drugs

Volumn 26, Issue 6, 2012, Pages 537-547

  Zucker, Inbar ^a,b   Chodick, Gabriel ^a,c   Grunhaus, Leon ^d   Raz, Ra'anan ^a   Shalev, Varda ^a,c  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b MINISTRY OF HEALTH   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d Jerusalem Mental Health Center Ezrath Nashim   (Israel)

Author keywords

antidepressants; bone loss; depression; fractures; Selective serotonin reuptake inhibitor

Indexed keywords

ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; FRACTURE; FRAGILITY FRACTURE; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; OSTEOLYSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; VALIDATION PROCESS;

ADULT; ANTICONVULSANTS; BONE DEMINERALIZATION, PATHOLOGIC; COHORT STUDIES; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRACTURES, BONE; HUMANS; ISRAEL; MEDICATION ADHERENCE; MIDDLE AGED; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84861900140     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11633300-000000000-00000     Document Type: Article

References (47)

1. Becker DJ, Kilgore ML, Morrisey MA. The societal burden of osteoporosis. Curr Rheumatol Rep 2010 Jun; 12 (3): 186-91
2. Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 2010 Oct; 123 (10): 877-84
3. Bolton JM, Targownik LE, Leung S, et al. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psycopharmacol 2011 Feb; 31 (1): 56-60
4. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 2006; 17 (6): 807-16 (Pubitemid 43781493)
5. Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 2003 Apr 28; 163 (8): 949-57 (Pubitemid 36519740)
6. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Canadian Multicentre Osteoporosis Study Research Group. Arch Intern Med 2007 Jan 22; 167 (2): 188-94 (Pubitemid 46148067)
7. Bolton JM, Metge C, Lix L, et al. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychophramcol 2008 Aug; 28 (4): 384-91
8. Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003 Jul 1; 158 (1): 77-84 (Pubitemid 36745333)
9. van den Brand MW, Pouwels S, Samson MM, et al. Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 2009 Oct; 20 (10): 1705-13
10. Verdel BM, Souverein PC, Egberts TC, et al. Use of anti-depressant drugs and risk of osteoporotic and nonosteoporotic fractures. Bone 2010 Sep; 47 (3): 604-9
11. Prozac: highlights of prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/018936s075s077lbl. pdf [Accessed 2011 Feb 21]
12. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009 Aug; 66 (8): 848-56
13. Bliziotes MM, Eshleman AJ, Zhang XW, et al. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 2001 Nov; 29 (5): 477-86 (Pubitemid 33026469)
14. Westbroek I, van der Plas A, de Rooij KE, et al. Expression of serotonin receptors in bone. J Biol Chem 2001 Aug 3; 276 (31): 28961-8
15. Battaglino R, Fu J, Späte U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 2004 Sep; 19 (9): 1420-31 (Pubitemid 41094343)
16. Bliziotes M, Gunness M, Eshelman A, et al. The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J Musculoskelet Neuronal Interact 2002 Mar; 2 (3): 291-5 (Pubitemid 34223826)
17. Warden SJ, Robling AG, Sanders MS, et al. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005 Feb; 146 (2): 685-93 (Pubitemid 40129824)
18. Warden SJ, Nelson IR, Fuchs RK, et al. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause 2008; 15 (6): 1176-83
19. Haney EM. Balancing bone health and mental health: a new clinical dilemma? Expert Rev Endocrinol Metab 2008; 3 (1): 1-3
20. Diem SJ, Blackwell TL, Stone KY, et al. Use of antidepressants and rates of hip bone loss in older women. Arch Intern Med 2007 Jun 25; 167 (12): 1240-5
21. Haney EM, Chan BK, Diem SJ, et al., for the Osteoporotic Fractures in Men Study Group. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007 Jun 25; 167 (12): 1246-51 (Pubitemid 46998495)
22. Spangler L, Scholes D, Brunner RL, et al. Depressive symptoms, bone loss and fractures in postmenopausal women. J Gen Intern Med 2008 May; 23 (5): 567-74
23. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Eng J Med 1996 Oct 17; 335 (16): 1176-81 (Pubitemid 26339771)
24. Cizza G, Primma S, Csako G. Depression as a risk factor for osteoporosis. Trends Endocrinol Metab 2009 Oct; 20 (8): 367-73
25. Ali II, Schuh L, Berkley GL, et al. Antiepileptic drugs and reduced bone mineral density. Epilpesy Behav 2004 Jun; 5 (3): 296-300 (Pubitemid 38950087)
26. Weng MY, Lane NE. Medication-induced osteoporosis. Curr Osteoporos Rep 2007 Dec; 5 (4): 139-45
27. Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in subjects using central nervous system-active medications. Am J Med 2005 Dec; 118 (12): 1414, e7-12
28. Karve S, Cleves MA, Helm M, et al. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health 2009 Sep; 12 (6): 989-95
29. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007 Jan-Feb; 10 (1): 3-12 (Pubitemid 46161090)
30. Sleath B, Domino ME, Wiley-Exley E, et al. Antidepressant and antipsychotic use and adherence among Medicaid youths: differences by race. Community Ment Health J 2010 Jun; 46 (3): 265-72
31. Israel Central Bureau of Statistics. 1995 Census population and housing. Jerusalem: Israel Central Bureau of Statistics, 1998
32. WHO. BMI classification [online]. Available from URL: http://apps.who.int/bmi/index.jsp?introPage=intro-3.html. [Accessed 2012 Apr 30]
33. Cox DR. Regression models and life tables. J R Stat Soc B Stat Methodol 1972; 34 (2): 187-220
34. Diem SJ, Blackwell TL, Stone KL, et al., for the Study of Osteoporotic Fractures Research Group. Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int 2011 June; 88 (6): 476-84
35. Vestergaard P, Rejmnark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 2008 Feb; 82 (2): 92-101
36. Ziere G, Dieleman JP, van der Cammen TJ, et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008 Aug; 28 (4): 411-7
37. Schwan S, Hallberg P. SSRIs, bone mineral density and risk of fractures: a review. Eur Nueropsychopharmacol 2009 Oct; 19 (10): 683-92
38. Cherin P, Colvez A, Deville de Periere G, et al. Risk of syncope in the elderly and consumption of drugs: a case-control study. J Clin Epidemiol 1997 Mar; 50 (3): 313-20 (Pubitemid 27167493)
39. Laursen AL, Mikkelsen PL, Rasmussen S, et al. Paroxetine in the treatment of depression-a randomized comparison with amitriptyline. Acta Psychiatr Scand 1985 Mar; 71 (3): 249-55 (Pubitemid 15169900)
40. Lee RH, Lyles KW, Colon-Emeric C. A review of the effect of anticonvulsant medication on bone mineral density and fracture risk. Am J Geriatr Pharmacother 2010 Feb; 8 (1): 34-46
41. Souverein PC, Webb DG, Weil JG, et al. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006 May 9; 66 (9): 1318-24 (Pubitemid 43739637)
42. Wu Q, Liu J, Gallegos-Orozco JF, et al. Depression, fracture risk and bone loss: a meta-analysis of cohort studies. Osteoporos Int 2010 Oct; 21 (10): 1627-35
43. Joling KJ, van Marwijk HW, der Horst HE, et al. Do GPs'medical records demonstrate a good recognition of depression? A new perspective on case extraction. J Affect Disord 2011 Oct; 133 (3): 522-7
44. Lee MS, Lee HY, Kang SG, et al. Variables influencing antidepressant medication adherence for treatning outpatients with depressive disorders. J Affect Disord 2010 Jun; 123 (1-3): 216-21
45. Milea D, Guelfucci F, Bent-Ennakhil N, et al. Antidepressant monotherapy: A claims database analysis of treatment changes and treatment duration. Clin Ther 2010 Nov; 32 (12): 2057-72
46. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007 Aug 1; 166 (3): 348-54 (Pubitemid 47216808)
47. Sheehan DV, Keene MS, Eaddy M, et al. Differences in medication adherence and healthcare resource utilization patterns: older vesrus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008; 22 (11): 963-73